API Export of Idraparinux sodium obtained from Indian Customs Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Idraparinux, 149920-56-9, Sanorg-34006, Sanorg34006, Org-34006, H84ixp29fn
Molecular Formula
C38H55Na9O49S7
Molecular Weight
1727.2  g/mol
InChI Key
MVPQUSQUURLQKF-MCPDASDXSA-E
FDA UNII
H84IXP29FN

Idraparinux sodium
1 2D Structure

Idraparinux sodium

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
nonasodium;(2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxane-2-carboxylate
2.1.2 InChI
InChI=1S/C38H64O49S7.9Na/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54;;;;;;;;;/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63);;;;;;;;;/q;9*+1/p-9/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-;;;;;;;;;/m1........./s1
2.1.3 InChI Key
MVPQUSQUURLQKF-MCPDASDXSA-E
2.1.4 Canonical SMILES
COC1C(OC(C(C1OC)OC)OC2C(C(C(OC2C(=O)[O-])OC3C(OC(C(C3OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC4C(C(C(OC4C(=O)[O-])OC5C(OC(C(C5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
2.1.5 Isomeric SMILES
CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)[O-])O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)[O-])O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
2.2 Other Identifiers
2.2.1 UNII
H84IXP29FN
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Idraparinux

2. Org 34006

3. Org-34006

4. Sanorg 34006

5. Sanorg-34006

6. Sr 34006

7. Sr-34006

8. Sr34006

2.3.2 Depositor-Supplied Synonyms

1. Idraparinux

2. 149920-56-9

3. Sanorg-34006

4. Sanorg34006

5. Org-34006

6. H84ixp29fn

7. Sr34006

8. Idraparinux Sodium (usan)

9. Sr-34006

10. Idraparinux Sodium [usan]

11. Sanorg 34006

12. Org 34006

13. Idraparinux Nonasodium Salt

14. Idraparinux Sodium [inn]

15. Unii-h84ixp29fn

16. Idraparinux Sodium [usan:inn]

17. Idraparinux Sodium [mart.]

18. Idraparinux Sodium [who-dd]

19. Idraparinux Nonasodium Salt [mi]

20. S-o-34006

21. D10471

22. Q3147909

23. Alpha-d-glucopyranoside, Methyl O-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuranosyl-(1-4)-, 2,3,6-tris(hydrogen Sulfate), Nonasodium Salt

24. Methyl (sodium 2,3,4-tri-o-methyl-6-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium 2,3-di-o-methyl-.beta.-d-glucopyranosylurate)-(1->4)-(trisodium 2,3,6-tri-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium -2,3-di-o-methyl-.alpha.-l-idopyranosyluronate)-(1->4)-(trisodium 2,3,6-tri-o-sulfonato-.alpha.-d-glucopyranoside)

25. Methyl O-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuronosyl-(1-4)-2,3,6-tri-o-sulfo-alpha-d-glucopyranoside Nonasodium

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 1727.2 g/mol
Molecular Formula C38H55Na9O49S7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count49
Rotatable Bond Count26
Exact Mass1725.8936149 g/mol
Monoisotopic Mass1725.8936149 g/mol
Topological Polar Surface Area761 Ų
Heavy Atom Count103
Formal Charge0
Complexity3190
Isotope Atom Count0
Defined Atom Stereocenter Count25
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count10
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Factor Xa Inhibitors

Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. (See all compounds classified as Factor Xa Inhibitors.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty